

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C07D 413/14, 417/14</b> <b>A61K 31/445</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/08718</b> <b>(43) International Publication Date:</b> 29 May 1992 (29.05.92)
<b>(21) International Application Number:</b> PCT/US91/05593 <b>(22) International Filing Date:</b> 16 August 1991 (16.08.91)  <b>(30) Priority data:</b> 612,776 14 November 1990 (14.11.90) US  <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 612,776 (CON) Filed on 14 November 1990 (14.11.90)  <b>(71) Applicant (for all designated States except US):</b> PFIZER INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).		<b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only) :</b> HOWARD, Harry, Ralph, Jr. [US/US]; 272 West Woods Terrace, Bristol, CT 06010 (US).  <b>(74) Agents:</b> LUMB, J., Trevor et al.; Pfizer Inc., Eastern Point Road, Groton, CT 06340 (US).  <b>(81) Designated States:</b> AT (European patent), BE (European patent), CA, CH (European patent), DE (European pa- tent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (Eu- ropean patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> 4-(1,2-BENZISOXAZOLYL)PIPERIDINE ANTIPSYCHOTIC AGENTS  <b>(57) Abstract</b>  Certain 1-substituted 4-(1,2-benzisoxazolyl)piperidine compounds exhibit neuroleptic activity and are useful in the treat- ment of psychosis and anxiety.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

<sup>+</sup> Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

## 5      4-(1,2-BENZISOXAZOLYL)PIPERIDINE ANTIPSYCHOTIC AGENTS

Background of the Invention


The present invention is directed to novel 1-substituted 4-(1,2-benzisoxazolyl)piperidine compounds which exhibit neuroleptic activity and are useful in the  
10 treatment of psychosis and anxiety.

Other compounds useful in treating psychotic disorders are known. For example, U.S. Patents Nos. 4,558,060 and 4,831,031 describe arylpiperazinyl-ethyl or butyl heterocyclic compounds and their use in the treatment of psychiatric  
15 disorders. European Patent Application 0196132 teaches 1,2-benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives useful in treating psychiatric disorders.

Although the above compounds have been discovered, there is a continual search in this field of art for other  
20 more effective compounds.

Summary of the Invention

This invention is directed to 1-substituted 4-(1,2-Benzisoxazolyl)piperidine compounds that are useful in the treatment of psychosis and anxiety. The compounds of this  
25 invention have the formula



30


**Formula I**

and the pharmaceutically acceptable base salts thereof; wherein

X is H, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy or CF<sub>3</sub>;

35 n is 2, 3 or 4; and

Q is



wherein Z is  $CR_2R_3$ ,  $CR_2R_3CR_4R_5$ ,  $CR_2R_3CR_4R_5CR_6R_7$ , O or S;  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$  and  $R_7$  are H, or  $C_1$ - $C_4$  alkyl;  $X_1$  and  $X_2$  are H or halo; and  $X_3$  is H,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy or  $CF_3$ . Solvates (e.g. hydrates) of the above compounds are also included within the scope of the definition of formula I.


Particularly preferred compounds are compounds of formula I wherein Z is  $CR_2R_3$  or  $CR_2R_3CR_4R_5$ . Preferred within this group are compounds where n is 2 and X is H or halo. Preferred within this group are compounds where X is halo,  $X_1$  and  $X_2$  are H, and  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  are H or methyl.

A second preferred group of compounds of formula I are those wherein Q is phenyl substituted with thiazolyl, said thiazolyl substituted with  $X_3$ . Preferred within this group are compounds wherein n is 4 and X is H, halo, or  $C_1$ - $C_4$  alkyl. The term "halo" refers to F, Cl or Br. A preferred compound within this group is 1-(4-(4-(2-methylthiazol-4-yl)phenyl)butyl)-4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine.


Other preferred compounds are 5-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyloxindole, 1,3-dimethyl-5-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-piperidinylethyl)oxindole, 3,3-dimethyl-5-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-piperidinyl)ethyl)oxindole, or 6-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidinyl)ethyl)-1,2,3,4-tetrahydro-2(1H)-quinolinone.

The present invention is also directed to pharmaceutical compositions for the treatment or prevention of psychosis and anxiety, which comprises a compound of the formula I and in a pharmaceutically acceptable carrier; and to a method for the treatment or prevention of psychosis or anxiety which comprises administering to a person in need of such treatment or prevention a compound of the formula I in an amount effective to treat or prevent psychosis or anxiety.


Other features and advantages will be apparent from the specification and claims.

Detailed Description of the Invention


II



III



IV




V




5

L-(CH<sub>2</sub>)<sub>n</sub>-Q



VI




I



5



10




15

20

-5-

5



XI

10



VI

15



Compounds of the formula I wherein X, n, Q, Z, X<sub>1</sub>, X<sub>2</sub>, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are as defined above may be prepared by reacting the appropriate formula V compounds wherein X is as defined above with the appropriate compounds of formula VI wherein X, n, Q, Z, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are as defined above and L is a halogen (e.g. F, Br, Cl, I) or other suitable leaving group (e.g. CH<sub>3</sub>SO<sub>3</sub>, p-toluenesulfonyloxy).

The reaction is generally performed in a polar solvent such as a lower alcohol, dimethylformamide, dimethylacetamide, acetonitrile, or methyl isobutyl ketone, and in the presence of a weak tertiary base such as triethylamine or an inorganic base such as sodium or potassium carbonate. A catalytic amount of sodium or potassium iodide may be employed to further the degree of completion. The reaction may be conducted at a temperature within the range of about

0°C to about 250°C, and preferably it is conducted at the reflux temperature (boiling point) of the chosen solvent.

The formula V compounds wherein X is as defined above may be made by a modification of a procedure disclosed in European Patent Application publication no. 0196132 described by Kennis et al. Generally a formula IV compound wherein X is as defined above and L<sub>1</sub> is a halogen or suitable leaving group is cyclized under basic conditions (e.g. 50% aqueous NaOH) at elevated temperatures of about 30°C to about 100°C and preferably at reflux.

The compounds of formula IV wherein X and L<sub>1</sub> are as described above may be made by reaction of the appropriate formula III compound wherein X and L<sub>1</sub> are as defined above with hydroxylamine hydrochloride and a base such as triethylamine or pyridine, in an inert solvent (e.g., a polar solvent such as a lower alcohol) under reflux conditions in the absence of oxygen.

The compounds of formula III wherein X and L<sub>1</sub> are as described above may be made by deacetylation of the appropriate formula II compound, wherein X and L<sub>1</sub> are as described above, by heating (e.g., at reflux) in the presence of an acid (e.g., conc. HCl) in the presence or absence of an inert solvent (e.g., acetic acid).

The compounds of formula II wherein X and L<sub>1</sub> are as described above may be made by methods known to those skilled in the art, such as by the Friedel Crafts acylation of the appropriately substituted benzene using an N-Acetylisonipecotoyl halide.

The compounds of formula VI wherein L, X, n, Q, Z, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are as defined above may be prepared by methods available to those practicing in the art and analogous to those described in European Patent Application 0281309. Thus, compounds of the formula VI (described above) may be prepared by reducing the appropriate compound of formula XI wherein L, X, n, Q, Z, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>,



$R_4$ ,  $R_5$ ,  $R_6$  and  $R_7$  are as defined above, with a reducing agent such as triethylsilane in trifluoroacetic acid.

Compounds of the formula XI wherein L, X, n, Q, Z,  $X_1$ ,  $X_2$ ,  $X_3$ ,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ , and  $R_7$  are as defined above may be prepared by reacting the appropriate compound of the formula IXA or IXB wherein X, Z,  $X_1$ ,  $X_2$ ,  $X_3$ ,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ , and  $R_7$  are as defined above with a haloalkanoic acid or a haloalkanoyl halide wherein the halogen is selected from the group consisting of Cl, Br and I, employing, for example, Friedel-Crafts conditions (e.g., aluminum trichloride in carbon disulfide or methylene dichloride under an inert atmosphere) or via acylation in a medium such as polyphosphoric acid at a temperature from about room temperature to about 100°C.

Formula Q compounds having the Formula IXA wherein phenyl is substituted with thiazoyl (the thiazolyl is optionally substituted with  $X_3$  as defined above) may be made by standard methods known to those skilled in the art such as described in Preparation E and EP Application 279,548.

Compounds of the formula IXB wherein  $X_1$ ,  $X_2$ ,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ , and  $R_7$  are as defined above and Z is  $CR_2R_3$ ,  $CR_2R_3CR_4R_5$ ,  $CR_2R_3CR_4R_5CR_6R_7$  may be made by several methods as described in the literature (e.g. U.S. Patent No. 4,831,031), and outlined above. For example, an aryl amine of formula VII wherein  $X_1$ ,  $X_2$  and  $R_1$  are as defined above may be converted using methods known in the art, to an arylamide of the formula VIII wherein  $X_1$ ,  $X_2$ ,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ , and  $R_7$  are as defined above and  $Q_2$  is a leaving group (e.g. halo) which may then be cyclized to produce a compound of the formula IXB.

Alternatively, compounds of formula VIII in which Z is C=O and  $Q_2$  is halo (i.e., Cl or Br) may be cyclized (e.g., employing Friedel-Crafts conditions as described above) to a compound of structure XII. These compounds of formula XII may then be reduced to compounds of formula IXB (where Z =  $CH_2$ ) using reduction techniques known to those skilled in the

art (e.g., by the Wolff-Kishner reduction, employing hydrazine and a strong base).

Compounds of the formula IXB wherein  $X_1$ ,  $X_2$ ,  $R_1$  are as defined above and Z is S or O may be prepared by standard methods known to those skilled in the art (e.g., U.S. Patent No. 4,831,031). In addition some are commercially available (e.g., 2-Benzoxazolinone is available from Aldrich Chem. Co.)

The pharmaceutically acceptable acid addition salts of the compounds of formula I are prepared in a conventional manner by treating a solution or suspension of the free base, i.e., a compound of formula I, with about one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration and recrystallization techniques are employed in isolating the salts. Such pharmaceutically acceptable acid addition salts include, but are not limited to the respective salts of acetic, malic, citric, fumaric, sulfuric, hydrochloric, hydrobromic, hydroiodic, sulfonic such as methanesulfonic and p-toluenesulfonic and related acids.

The neuroleptic activity of the present compounds may be demonstrated by methods based on standard procedures. In one method, adult male Sprague-Dawley rats are pretreated with appropriate doses of the test compound by subcutaneous injection. One half hour later all rats are injected intraperitoneally with 1 mg/kg apomorphine hydrochloride dissolved in an 0.1% ascorbate solution. The rats are rated behaviorally according to the following scale at 5, 15, 25, 35 and 45 minutes after the apomorphine injection: 0 = alert but not moving, 1 = moving around the cage, 2 = discontinuous sniffing behavior, 3 = continuous sniffing with discontinuous oral movements, and 4 = continuous licking and chewing movements.

The neuroleptic activity of the compounds of this invention makes them useful for treating psychotic disorders in human subjects. For example, these compounds are useful for treating psychotic disorders of the schizophrenic types

and in particular the compounds are useful for removing or ameliorating such symptoms as anxiety, agitation, excessive aggression, tension and social or emotional withdrawal in psychotic patients.

5       A neuroleptic compound of the formula I or a pharmaceutically-acceptable salt thereof can be administered to a human subject either alone or preferably in combination with pharmaceutically-acceptable carriers or diluents in a pharmaceutical composition according to standard pharmaceutical practice. A compound can be administered orally or  
10       parenterally. Parenteral administration includes especially intravenous and intramuscular administration. Additionally, in a pharmaceutical composition comprising a compound of formula I or a pharmaceutically-acceptable salt thereof, the  
15       weight ratio of active ingredient to carrier will normally be in the range from about 1:6 to about 2:1 and preferably from about 1:4 to about 1:1. However, in any given case, the ratio chosen will depend on such factors as the solubility of the active component, the dosage contemplated  
20       and the precise route of administration.

For oral use of a neuroleptic agent of this invention, the compound can be administered, for example, in the form of tablets or capsules or as an aqueous solution or suspension. In the case of tablets for oral use, carriers which  
25       can be used include lactose and corn starch, and lubricating agents such as magnesium stearate can be added. For oral administration in capsule form, useful diluents are lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient can be combined  
30       with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents can be added. For intramuscular and intravenous use, sterile solutions of the active ingredient can be prepared and the pH of the solutions should be suitably adjusted and buffered. For  
35       intravenous use the total concentration of solutes should be controlled to render the preparation isotonic.

When a neuroleptic agent of this invention is to be used in a human subject to treat a psychotic disorder, the daily dosage will normally be determined by the prescribing physician. Moreover, the dosage will vary according to the age, weight and response of the individual patient as well as the severity of the patient's symptoms. However, in most instances an effective amount for treating a psychotic disorder will be a daily dosage in the range from about 3 mg to about 600 mg and preferably from about 30 mg to about 60 mg in single or divided doses, orally or parenterally. In some instances, it may be necessary to use dosages outside these limits.

The present invention is illustrated by the following examples, but is not limited to the details thereof.

15

EXAMPLE 15-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)oxindole

Under N<sub>2</sub> a mixture of 4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine V (2.0 g, 9.08 mmol), 5-(2-chloroethyl)-oxindole (0.95 g, 10 mmol), Na<sub>2</sub>CO<sub>3</sub> (1.06 g, 10 mmol) and KI (1.0 g, 6.0 mmol) in 45 ml dry DMF was heated at 90°C for 72 hours. The reaction mixture was then poured over 150 ml ice/water, stirred, and filtered to give 3.04 g of brown solids. Chromatography on silica gel (230-400 mesh), eluting with 95% EtOAc: 5% triethylamine provided clean product, 0.645 g (19%), light brown solid, m.p. 199-204°C. Analysis for C<sub>22</sub>H<sub>22</sub>FN<sub>3</sub>O<sub>2</sub> · 0.5H<sub>2</sub>O: C 68.03, H 5.97, N 10.82. Found: C 67.94, H 5.57, N 10.81; MS(%): 379 (1, p<sup>+</sup>), 253 (4), 234 (32), 233 (100). NMR (300 MHz, CDCl<sub>3</sub>, delta), 2.0-2.4 (m, 6H), 2.65 (m, 2H), 2.8 (m, 2H), 3.1-3.2 (m, 3H), 3.5 (s, 2H), 6.75 (d, 1H), 7.1 (m, 3H), 7.2 (s, 1H), 7.7 (m, H), 8.25 (br s, 1H).

30

EXAMPLES 2-5

By a similar procedure the following were also prepared:

35

2. 1,3-dimethyl-5-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidinyl)ethyl)oxindole hydrochloride

35%, m.p. 104°C (dec.). Analysis for  $C_{24}H_{26}FN_3O_2 \cdot HCl \cdot 1.5H_2O$ : C 61.21, H 6.42, N 8.92. Found: C 61.28, H 6.40, N 8.64. MS(%): 407 (3, p<sup>+</sup>), 233 (100).

- 5 3. 3,3-dimethyl-5-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidiny)ethyl)oxindole hydrochloride hydrate

21%, m.p. 268°C (dec.). Analysis for  $C_{24}H_{26}FN_3O_2 \cdot HCl \cdot 0.25 H_2O$ : C 64.28, H 6.18, N 9.37. Found: C 64.33, H 5.79, N 9.10. MS(%): 407 (3, p<sup>+</sup>), 269(4), 233 (100).

- 10 4. 6-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidiny)ethyl)-1,2,3,4-tetrahydro-2(1H)-quinolinone hemihydrate

50%, m.p. 193-195°C. Analysis for  $C_{23}H_{24}FN_3O_2 \cdot 0.5H_2O$ : C 68.64, H 6.26, N 10.44. Found: C 68.65, H 5.94, N 10.13; MS(%): 393 (2, p<sup>+</sup>), 233(100).

- 15 5. 1-(4-(4-(2-methylthiazol-4-yl)phenyl)butyl)-4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine dihydrochloride hemihydrate

34%, m.p. 188-189°C. Analysis for  $C_{26}H_{28}FN_3OS \cdot 2HCl \cdot 0.5H_2O$ : C 58.75, H 5.88, N 7.91. Found: C 58.40, H 5.96, N 7.80; MS(%): 451 (6), 450 (20), 449 (52, p<sup>+</sup>), 311 (33), 233 (100).

#### PREPARATION A

- 25 4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidine hydrochloride (V)

N-Acetyl isonipecotoyl chloride (70.0 g, 0.369 mol) was added over a 20 minute period to a vigorously stirred suspension of  $AlCl_3$  (98 g, 0.735 mol) in 1,3-difluorobenzene (125 ml, 1.27 mol, Aldrich Chem. Co.) at 25°C. The mixture was then refluxed, under  $N_2$  for 4.5 hours, cooled to 25°C, and poured over 300 ml of ice/water. The layers were separated, the aqueous layer was extracted (2 x 100 ml  $CH_2Cl_2$ ) and combined with the organic layer and dried with  $MgSO_4$ . Concentration in vacuo gave 4-(2,4-difluorobenzoyl)1-acetylpiperidine (II) as a white solid (81 g, 82%), m.p. 94-96°C.

The preceding ketone (40 g, 0.15 mol) was added to a mixture of 125 ml concentrated HCl and 125 ml acetic acid and refluxed for 16 hours, cooled, and concentrated in vacuo. The white residue was triturated with hot isopropanol, filtered, washed with Et<sub>2</sub>O and dried to give 32.3 g (83%) of 4-(2,4-difluorobenzoyl)-piperidine hydrochloride (III), m.p. 215-216°C.

The above material (32 g, 0.122 mol), hydroxylamine·HCl (8.5 g, 0.122 mol) and triethylamine (24.8 g, 0.224 mol) in EtOH (250 ml) was refluxed under N<sub>2</sub> for 4 hours, cooled and filtered to provide the oxime (IV), 27.44 g (93%), m.p. 246-252°C.

Crude IV in 300 ml of 50% aqueous NaOH was refluxed for 4 hours, cooled and extracted with toluene (3 x 100 ml). The organic extracts were washed with saturated NaCl, dried (MgSO<sub>4</sub>) and concentrated to a yellow residue. Chromatography on silica gel (230-400 mesh) eluting with 19 CH<sub>2</sub>Cl<sub>2</sub>:1 CH<sub>3</sub>OH:0.1 NH<sub>4</sub>OH produced the title product (V), converted to its hydrochloride with HCl gas in Et<sub>2</sub>O, 5.0 g (17%), m.p. 295°C (dec.).

#### PREPARATION B, C

The substituted 5-(2-chloroethyl)oxindoles used in Examples 2 and 3 were prepared in an analogous fashion to preparation D from the appropriate starting materials (i.e., 1,3-dimethyloxindole and 3,3-dimethyloxindole, respectively).

#### PREPARATION D

##### 6-(2-chloroethyl)-1,2,3,4-tetrahydro-2(1H)-quinolinone

Under N<sub>2</sub> a mixture of chloroacetyl chloride (5.2 ml, 0.065 mol) and AlCl<sub>3</sub> (41.4 g, 0.31 mol) in 200 ml CS<sub>2</sub> was stirred mechanically while 1,2,3,4-tetrahydro-2(1H)quinolinone (7.36 g, 0.05 mol, prepared according to the method of JACS, 1944, 66, 1442) was added over a 5 minute period. The mixture was refluxed for 2 hours and another 20 ml chloroacetyl chloride was added. After a further 3 hours at reflux, the dark green reaction mixture was cooled to 25°C,

the CS<sub>2</sub> was decanted, and the residue was slowly decomposed by pouring slowly over 500 g ice. (NOTE: vigorous evolution of HCl!) The resulting solids were filtered, washed well with H<sub>2</sub>O and air dried to give 10.7 g (96%) of crude  
5 6-chloroacetyl-1,2,3,4-tetrahydro-2(1H)quinolinone, m.p. 215-218°C; MS(%): 233 (9, p<sup>+</sup>), 174 (100).

Under N<sub>2</sub>, the above intermediate (6.71 g, 0.03 mol) in trifluoroacetic acid (23 ml, 0.3 mol) was treated dropwise with triethylsilane (11 ml, 0.069 mol) while maintaining an  
10 internal temperature below 25°C. After 72 hours at 25°C the brown solution was poured over 200 ml ice/water and stirred to produce a tan solid which was further washed with water and dried to give the title product, 5.42 g (86%), m.p. 148-152°C (dec.); MS(%): 211, 209 (34, p<sup>+</sup>), 160(100). NMR  
15 (d<sub>6</sub>-DMSO, 300MHz, delta), 2.0-2.3 (m, 2H), 2.4-2.75 (m, 4H), 3.4 (t, 2H), 6.4 (d, 1H), 6.6-6.8 (m, 2H), 9.7 (br s, 1H).

#### PREPARATION E

The chlorobutyl thiazolyl substituted phenyl used in Example 5 was prepared according to the following method and  
20 as described in E.P. Application 279,598.

4-Chlorobutylacetophenone: To a 250 ml round-bottomed flask were added 5.0 g (29.65 mmol) 1-chloro-4-phenylbutane and 10 ml 1,2-dichloroethane. To the stirred solution was added a solution of 4.35 g (32.62 mmol) aluminum chloride  
25 and 4.22 ml (59.31 mmol) acetyl chloride in 50 ml 1,2-dichloroethane. The solution evolved HCl as it was stirred at room temperature for 1 hour. It was then poured into water, the layers separated, and the organic layer washed with 1N HCl, aqueous sodium bicarbonate solution, brine,  
30 dried over sodium sulfate, and evaporated to an oil, 6.7 g (100%). NMR (delta, CDCl<sub>3</sub>): 1.76 (m, 4H), 2.5 (s, 3H), 3.50 (m, 2H), 7.2 and 7.85 (m, 4H). IR cm<sup>-1</sup>, neat): 1678 (C = O).

4-(4-Chlorobutyl)phenyl-2-methylthiazole hydrobromide: The  
35 above oil was added to a 100 ml round-bottomed flask equipped with N<sub>2</sub> inlet along with 15 ml acetic acid. Bromine

(1.53 ml, 29.65 mmol) was added dropwise and the solution stirred at room temperature for 15 minutes (decolorizes in about 7 minutes). The solution was taken up in ethyl acetate (careful - the bromide is a potent lachrymator),  
5 washed with water, aqueous sodium bicarbonate solution, brine, dried over sodium sulfate, and evaporated to an oil, 8.9 g (about 100% yield).

The oil was dissolved in 70 ml acetone, treated with 2.23 g (29.65 mmol) thioacetamide (which gives a precipi-  
10 tate, which, however, is not product) and refluxed 15 hours. The reaction was cooled, evaporated to 10 ml volume to afford a precipitate, filtered, the precipitate washed with 10 ml acetone, then washed thoroughly with ether and dried to a white solid, mp 128-129°C, 6.8 g (66.2%). NMR (delta,  
15 DMSO-d<sub>6</sub>): 1.85 (m, 4H), 2.5 (m, 2H), 2.77 (s, 3H), 3.5 (m, 2H), 7.2 and 7.8 (m, 4H), 7.92 (s, 1H). IR (cm<sup>-1</sup>, DMSO): 1620. MS (%): 265/267 (parent, 7.5/3.7), 189 (17), 188 (100), 147 (39), 115 (11), 82 (10).




5

CLAIMS


1. A 4-(1,2-Benzisoxazolyl)piperidine compound of the formula

10



Formula I

- and the pharmaceutically acceptable base salts thereof  
 15 wherein X is H, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy or CF<sub>3</sub>;  
 n is 2, 3 or 4; and  
 Q is



- wherein Z is CR<sub>2</sub>R<sub>3</sub>, CR<sub>2</sub>R<sub>3</sub>CR<sub>4</sub>R<sub>5</sub>, CR<sub>2</sub>R<sub>3</sub>CR<sub>4</sub>R<sub>5</sub>CR<sub>6</sub>R<sub>7</sub>, O or S; R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>,  
 20 R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are H or C<sub>1</sub>-C<sub>4</sub> alkyl; X<sub>1</sub> and X<sub>2</sub> are H or halo;  
 and X<sub>3</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy or CF<sub>3</sub>.

2. A compound according to claim 1 wherein Z is CR<sub>2</sub>R<sub>3</sub> or CR<sub>2</sub>R<sub>3</sub>CR<sub>4</sub>R<sub>5</sub>.

3. A compound according to claim 2 wherein n is 2 and  
 25 X is H or halo.

4. A compound according to claim 3 wherein X is halo, X<sub>1</sub> and X<sub>2</sub> are H, and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are H or methyl.

5. A compound according to claim 1 said compound being 5-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperi-  
 30 danyl)ethyl)oxindole, 1,3-dimethyl-5-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidiny)ethyl)oxindole, 3,3-dimethyl-5-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidiny)ethyl)oxindole, or 6-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidiny)ethyl)-1,2,3,4-tetrahydro-2(1H)-quinoli-  
 35 none.

6. A compound according to claim 1 wherein Q is phenyl substituted with thiazolyl, said thiazolyl substituted with  $X_3$ .


7. A compound according to claim 6 wherein n is 4 and  $X_3$  is H, or  $C_1$ - $C_4$  alkyl.

8. A compound according to claim 7 said compound being 1-(4-(4-(2-methylthiazol-4-yl)phenyl)butyl)-4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine.

9. A pharmaceutical composition for the treatment or prevention of psychosis and anxiety, which comprises a compound according to claim 1 in a pharmaceutically acceptable carrier.

10. A method for the treatment or prevention of psychosis or anxiety, comprising administering to a person in need of said treatment or prevention a compound according to claim 1 in an amount effective to treat or prevent psychosis or anxiety.

11. A process for preparing a 4-(1,2-benzisoxazolyl)-piperidine compound of the formula




Formula I

and the pharmaceutically acceptable base salts thereof wherein X is H, halo,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy or  $CF_3$ ;

n is 2, 3 or 4; and

Q is




wherein Z is  $CR_2R_3$ ,  $CR_2R_3CR_4R_5$ ,  $CR_2R_3CR_4R_5CR_6R_7$ , O or S;  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$  and  $R_7$  are H or  $C_1$ - $C_4$  alkyl; and  $X_1$  and  $X_2$  are H

-17-

or halo; and  $X_3$  is H,  $C_1-C_4$  alkyl,  $C_1-C_4$  alkoxy or  $CF_3$ , which comprises reacting a compound of the formula V

5



V

where X is as defined, with a base, a catalytic amount  
10 of an alkali metal salt and a compound of the formula VI



VI

15

in a polar solvent, where n and Q are as defined and L is a halo or other suitable leaving group, until the reaction is substantially complete.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US 91/05593

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 07 D 413/14, 417/14, A 61 K 31/445		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
IPC5	C 07 D	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	EP, A1, 0079564 (HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED) 25 May 1983, see the whole document  --	1-9, 11
X	EP, A2, 0196132 (JANSSEN PHARMACEUTICA N.V.) 1 October 1986, see the whole document  --  -----	1-9, 11
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents:<sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
11th December 1991	13 JAN 1992	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	MISS T. TAZELAAR	

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE<sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 10, because it s they relate to subject matter not required to be searched by this Authority, namely:

Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods (see PCT Rule 39(iv)).

2. ☐ Claim numbers....., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING<sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the the claims. It is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. PCT/US 91/05593**

SA 51029

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on 31/10/91  
The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0079564	25/05/83	AU-B- 556307	30/10/86
		AU-D- 9039182	19/05/83
		CA-A- 1196334	05/11/85
		JP-A- 58090583	30/05/83
		US-A- 4352811	05/10/82
EP-A2- 0196132	01/10/86	AU-B- 579232	17/11/88
		AU-D- 5529786	02/10/86
		CA-A- 1256867	04/07/89
		JP-A- 61221186	01/10/86
		SU-A- 1468419	23/03/89
		US-A- 4804663	14/02/89

For more details about this annex : see Official Journal of the European patent Office,

EPO FORM P0478

App. No. 10/088,369  
Filed: December 23, 2002  
Inventor: LEE, et. al.  
Docket No. HMR2021 US GNT  
**PRIOR ART**